4506
Fiscal year ends March Quarters are offset from the calendar — Q1 is Apr–Jun

Sumitomo Pharma Co., Ltd. is a pharmaceutical company engaged in the manufacturing, procurement, and sale of medical drugs. The company operates through three main segments: Japan, North America, and Asia. In Japan, it manages the production and distribution of pharmaceuticals, including authorized generic products through Sumitomo Pharma Promo. The company also operates joint ventures in regenerative and cell therapy, including S-RACMO for process development and manufacturing, and RACTHERA for research and development. In North America, Sumitomo Pharma America, Inc. handles the manufacturing and sales of medical drugs. In Asia, the company collaborates with Marubeni Pharmaceutical for the production and distribution of pharmaceuticals. The group structure includes ten subsidiaries and four associated companies that provide business support services.

Summarised from the annual report, fiscal year ended Mar 2026

Industry Drug Manufacturers - General Homepage sumitomo-pharma.com
Sector Healthcare IR page sumitomo-pharma.com
Tags
pharmaceuticals, authorized generics, regenerative medicine, cell therapy, medical drugs, joint ventures, Sumitomo Pharma Promo, S-RACMO, RACTHERA, Sumitomo Pharma America Inc., Marubeni Pharmaceutical
Press page sumitomo-pharma.com/news

Metrics

Valuation  
Market cap ¥ 702.107B
Market cap (USD) $ 4.399B
P/E 14.66
PEG —
P/BV 1.63
P/S 1.43
P/OCF 9.98
P/FCF 10.69
Dividend yield 1.3%
Turnover / mcap —
Returns  
ROE 46.3%
ROI 21.0%
ROIC 21.1%
Profit margin 23.6%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 1
Quality score 33.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 453.294B 398.832B 314.558B 555.544B 560.035B 515.952B 482.732B 459.267B 477.966B 411.638B 403.206B 371.37B 387.693B 347.724B
Net profit 106.865B 23.634B -314.969B -74.512B 56.413B 56.219B 40.753B 48.627B 37.525B 28.991B 24.697B 15.447B 20.06B 10.043B
Free cash flow 64.403B 3.47B -252.664B -805M 17.745B 124.795B 32.777B 35.797B — 8.165B 39.675B — — —

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 2.077K 726.69 — 1.209K 1.209K 1.93K 1.4K 2.741K 1.785K 1.836K 1.295K 1.423K 1.64K 1.755K
Price performance 12m 1.86 — — 0 -0.37 0.38 -0.49 0.54 -0.03 0.42 -0.09 -0.13 -0.07 —

Filed figures

Figure Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Balance sheet detail
Trade receivables (JPY) 111B 113B 119B 134B 136B 151B 95.9B 81B 74.8B 131B
↳ YoY growth +3.5% +5.1% +13.2% +1.0% +11.4% -36.7% -15.5% -7.6% +75.6%
↳ 5y CAGR -3.2% -7.4% -11.1% -0.7%
Borrowings, current (JPY) 58B 16.5B 2.96B 273B 9.96B 25.1B 90.6B 286B 46.4B 38.1B
Borrowings, non-current (JPY) 10B 30.9B 28B 25B 264B 244B 244B 133B 259B 179B
Bonds payable (JPY) 20B — — — — — — — — —
Cash and deposits (JPY) 106B 148B 137B 102B 194B 203B 143B 29B 23.1B 44.3B
Intangible assets (JPY) 304B 190B 171B 422B 383B 399B 329B 196B 173B 160B
Net debt (borrowings + leases - cash) (JPY) -3.41B -100B -106B 196B 80.1B 66.1B 191B 390B 282B 173B
Cash flow detail
Operating cash flow (JPY) 21.6B 96.3B 48.7B 46.1B 136B 31.2B 11.9B -242B 16.5B 71.7B
Purchases of property, plant and equipment (JPY) -8.13B -5.13B -9.27B -7.72B -6.05B -7.35B -8.47B -10.8B -8.5B -4.61B
Purchases of intangible assets (JPY) -5.33B -7.23B -3.65B -5.63B -4.76B -6.15B -4.28B -4.96B -4.53B -2.7B
Change in receivables (cash effect) (JPY) -3.73B -2.93B -3.63B -16.4B 185M -6.1B 51.2B 23.4B -909M -50.8B
Change in inventories (cash effect) (JPY) -9.27B -4.38B -3.21B -14.4B -10B 5.36B 4.56B -11.8B 18.8B 9.01B
Change in payables (cash effect) (JPY) 2.97B 10.5B -10.9B 15.2B -320M -28.7B 5.32B 5.65B -25.9B 24.4B
Dividends paid (cash effect) (JPY) -7.15B -7.94B -11.1B -13.1B -11.1B -11.1B -11.1B -2.79B -3M -2M
Interest paid (cash effect) (JPY) -351M -338M -144M -1.53B -2.23B -2.5B -2.42B -3.73B -4.36B -4.49B
Income taxes paid (cash effect) (JPY) -45.8B -13.8B -23.5B -25.9B -35B -42.3B -25.5B -37.6B -1.89B -4.56B
Operating cash flow before change in receivables (JPY) 25.4B 96.4B 52.3B 62.5B 135B 37.3B -39.3B -265B 17.4B 122B
Free cash flow (OCF - PPE - intangibles) (JPY) 8.17B 81.1B 35.8B 32.8B 125B 17.7B -805M -258B 3.47B 64.4B
Income detail
Research and development expense (JPY) 80.8B 86.9B 102B 115B 133B 94.9B 132B 113B 49.9B 44B
↳ 5y CAGR +8.7% +1.9% -15.4% -19.8%
Total comprehensive income (JPY) 20.9B 30.6B 56.2B 39.9B 41B 28.2B -35.1B -250B 13.4B 123B
Comprehensive income to owners (JPY) 29.8B 48.4B 56.2B 45.7B 61B 37.6B -19.9B -250B 13.4B 123B
Segments
Asia · Segment revenue (JPY) — — — — — — 43.5B 40.9B 47.2B 23B
↳ YoY growth -6.0% +15.5% -51.2%
Asia · Segment operating income (JPY) — — — — — — 21.4B 18.4B 23.9B 9.45B
China · Segment revenue (JPY) — 23.4B 24.7B 28.6B 27.8B 38.3B 39.4B — — —
↳ YoY growth +5.6% +15.6% -2.7% +37.6% +2.9%
China · Segment operating income (JPY) — 10.7B 12.3B 14.4B 13.2B 19.6B 19.5B — — —
Japan · Segment revenue (JPY) — 143B 129B 140B 153B 150B 126B 115B 99.8B 92.4B
↳ YoY growth -9.8% +8.0% +9.2% -1.7% -15.9% -9.1% -12.9% -7.5%
Japan · Segment operating income (JPY) — 40.3B 25.1B 22.9B 24.3B 19.6B 9.07B 13.4B 11.4B 12.4B
North America · Segment revenue (JPY) — 241B 253B 262B 281B 320B 328B 159B 252B 338B
↳ YoY growth +4.9% +3.9% +7.3% +13.6% +2.7% -51.6% +58.3% +34.2%
North America · Segment operating income (JPY) — 110B 115B 118B 117B 105B 32.2B -80.2B 42.6B 75.7B
Other Regions · Segment revenue (JPY) 11.6B 16.5B 14.3B 14.8B 17.2B 12.2B 16.8B — — —
↳ YoY growth +3.4% -13.2% +3.5% +16.5% -29.3% +37.6%
Other Regions · Segment operating income (JPY) 2.8B 5.13B 5.01B 6.4B 8.69B 3.25B 9.99B — — —
Reported Jun 19, 2018 Jun 20, 2019 Jun 20, 2019 Jun 23, 2020 Jun 24, 2021 Jun 23, 2022 Jun 25, 2024 Jun 25, 2024 Jun 26, 2025 Jun 23, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

ene20261105_1.pdf Bull 4 Bear 0 Clinical/regulatory

Sumitomo Pharma America to Present New Clinical Data on Enzomenib and Nuvisertib at the 2026 American Society of Hematology Annual Meeting –

SMPA to present first data from ongoing Phase 2 clinical trial of enzomenib in patients with relapsed or refractory acute leukemia, with KMT2A rearrangements, an aggressive subtype of leukemia –

–

Completed dose optimization study of enzomenib in patients with relapsed or refractory acute myeloid leukemia with NPM1 mutation demonstrated enzomenib 300 mg twice a day was generally well tolerated with measurable clinical activity –

–

Preliminary clinical data from ongoing Phase 1/2 study of nuvisertib in combination with momelotinib show encouraging clinical responses in patients with relapsed or refractory myelofibrosis –

MARLBOROUGH, Mass., November 4, 2026 – Sumitomo Pharma America, Inc. (SMPA) today announced two oral presentations and two poster presentations at the 68th American Society of Hematology (ASH) Annual Meeting & Exposition, taking place December 12-15, 2026, in New Orleans, Louisiana. The presentations will feature new clinical data on enzomenib, an investigational oral small molecule menin inhibitor being studied in genetic subtypes of relapsed or refractory (R/R) acute leukemia (AL), and nuvisertib, an investigational oral small molecule highly selective PIM1 kinase inhibitor with added ACVR1 inhibition being evaluated in combination with momelotinib (MMB) in patients with R/R myelofibrosis (MF). “There remains a high unmet medical need for patients with R/R acute myeloid leukemia with KMT2Ar or NPM1m for targeted therapies that yield robust response rates and durable response that are well tolerated," said Jatin Shah, M.D., Chief Medical Officer, Oncology, SMPA. “In addition, new classes of therapeutics and combination strategies to potentially improve upon the activity of JAK inhibitors are important in MF. With this in mind, we look forward to sharing encouraging new data that further support the therapeutic potential and development of our late-stage oncology pipeline at ASH." For enzomenib, the oral presentation will report efficacy and safety data from the pivotal Phase 2 arm of the Horizen-1 study in patients with R/R KMT2A rearrangements (KMT2Ar) AL. The data will highlight the therapeutic potential of enzomenib as a targeted treatment option for patients with this high-risk subset of AL. Additionally, a poster presentation will include clinical findings from the completed dose optimization study of enzomenib that informed the recommended Phase 2 dose (RP2D) in patients with R/R AL with NPM1 mutation (NPM1m). The data demonstrated that both 200 mg twice a day (BID) and 300 mg BID of enzomenib were generally well tolerated with measurable clinical activity. Objective response rates (ORRs) were 54% and 57% in patients receiving 200 and 300 mg BID, respectively, while the complete remission and complete remission with partial hematologic recovery (CR+CRh) rates were 35% at 200 mg BID and 43% at 300 mg BID.

For nuvisertib, the oral presentation will report preliminary findings from the ongoing global Phase 1 dose escalation study evaluating nuvisertib and MMB in patients with MF previously treated with a JAK inhibitor show the combination appeared to be well tolerated in the dose levels evaluated. Promising clinical activity included symptom and spleen responses, anemia improvement, and cytokine modulation. These emerging clinical data support the Phase 3 clinical development of nuvisertib in combination with MMB for patients with MF and anemia. Presentation Details Title

Details

Presenting Author

Investigational PIM1 kinase inhibitor nuvisertib in combination with momelotinib showed promising clinical activity in patients with myelofibrosis and anemia: Preliminary data from an ongoing Phase 1/2 study

Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Combining Forces Against Myelofibrosis

Lindsay A.M. Rein, M.D.

Oral Presentation

9:30—11 a.m. CST

Sunday, December 13, 2026

Presentation Time: 9:45— 10 a.m. CST Room: R02-R05 (New Orleans Ernest N. Morial Convention Center) Selective PIM1 inhibition with nuvisertib promotes megakaryocyte maturation and platelet production in myelofibrosis patients

Session: 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster I

Poster Presentation

Saturday, December 12, 2026 5:30—7:30 p.m. CST Room: Hall F (New Orleans Ernest N. Morial Convention Center)

Lilian Varricchio, Ph.D.

Initial report of the Phase 2 pivotal data in patients with relapsed or refractory KMT2Ar acute leukemia from the phase 1/2 trial of the investigational menin inhibitor enzomenib (DSP5336) Oral Presentation

Session: 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies - Novel Combinations with Menin, FLT3 and BCL2 Inhibitors

Harry P. Erba, M.D., Ph.D.

Sunday, December 13, 2026 4:30—6 p.m. CST Presentation Time: 5—5:15 p.m. CST Room: Hall B (New Orleans Ernest N. Morial Convention Center)

Enzomenib dose optimization and determination of the recommended Phase 2 dose in patients (pts) with relapsed or refractory NPM1m acute leukemia Poster Presentation

Session: 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster III

Cristina Papayannidis, M.D., Ph.D.

Monday, December 14, 2026 6—8 p.m. CST Presentation Time: 6—8 p.m. CST Room: Hall F (New Orleans Ernest N. Morial Convention Center)

About Enzomenib (DSP-5336) Enzomenib is an investigational, oral, small molecule inhibitor of the menin and lysine (K)specific methyltransferase 2A (KMT2A) protein interaction, a key interaction in acute leukemia and other tumor cell proliferation and growth.1 Menin is a scaffold nuclear protein that plays key roles in gene expression and protein interactions involved in many biological pathways, including cell growth, cell cycle, genomic stability, and hematopoiesis.2,3 In preclinical studies, enzomenib has shown selective growth inhibition in human acute leukemia cell lines with KMT2A rearrangements or NPM1 mutations.4 Enzomenib reduced the expression of the leukemia-associated genes HOXA9 and MEIS1 and increased the expression of the

differentiation gene CD11b in human acute leukemia cell lines with KMT2A rearrangements or NPM1 mutations.1,4 The safety and efficacy of enzomenib are currently being clinically evaluated in a Phase 1/2 dose-escalation/dose-expansion study in patients with relapsed or refractory acute leukemia (NCT04988555) and the registrational Phase 2 Horizen-1 R/R mono AML/ALL (KMT2Ar + NPM1m) study. The FDA granted Orphan Drug Designation for enzomenib for the indication of acute myeloid leukemia in June 2022 and the indication of acute lymphoblastic leukemia in July 2026. The FDA granted Fast Track Designation for enzomenib for the indication of relapsed or refractory acute myeloid leukemia with KMT2Ar or NPM1m in June 2024 and Breakthrough Therapy Designation for the treatment of patients with relapsed/refractory acute leukemia with KMT2Ar in October 2026. Japan's Ministry of Health, Labour and Welfare (MHLW) granted Orphan Drug Designation for enzomenib for the indication of relapsed or refractory acute myeloid leukemia with KMT2Ar or NPM1m in September 2024. About Nuvisertib (TP-3654) Nuvisertib is an oral investigational selective inhibitor of PIM1 kinase with added ACVR1 inhibition, which has shown potential antitumor and antifibrotic activity through multiple pathways, including induction of apoptosis in preclinical models.5-7 Nuvisertib was observed to inhibit proliferation and increase apoptosis in murine and human hematopoietic cells expressing the clinically relevant JAK2 V617F mutation.6 Nuvisertib alone and in combination with ruxolitinib showed reduction of spleen size and bone marrow fibrosis in JAK2 V617F and MPLW515L murine models of myelofibrosis.6 In addition to its primary activity against PIM1, nuvisertib has been shown to bind and inhibit ACVR1 in preclinical studies, which may contribute to hemoglobin responses in patients with myelofibrosis.7 The safety and efficacy of nuvisertib monotherapy or in combination with a JAK inhibitor are currently being clinically evaluated in a Phase 1/2 study in patients with intermediate- and high-risk myelofibrosis (NCT04176198). The FDA granted Orphan Drug Designation to nuvisertib for the indication of myelofibrosis in May 2022. The Japan Ministry of Health, Labour and Welfare (MHLW) granted Orphan Drug Designation to nuvisertib for the treatment of myelofibrosis in November 2024. The European Medicines Agency (EMA) granted Orphan Drug Designation to nuvisertib for the treatment of myelofibrosis in July 2025. The FDA granted Fast Track Designation to nuvisertib for the indication of myelofibrosis in June 2025. About Sumitomo Pharma Sumitomo Pharma Co., Ltd. is a global pharmaceutical company based in Japan with key operations in the U.S. (Sumitomo Pharma America, Inc.) focused on developing and delivering innovative pharmaceutical and regenerative medicines to meet patient needs across oncology, urology, women's health, rare diseases, and CNS. With several marketed products in the U.S. and Europe, and a diverse pipeline of early- to late-stage assets, we aim to accelerate discovery, research, and development to bring novel therapies to patients sooner. For more information on SMPA, visit our website https://www.us.sumitomo-pharma.com or follow us on LinkedIn.

The Sumitomo corporate symbol mark is a registered trademark of Sumitomo Pharma Co., Ltd., used under license. SUMITOMO PHARMA is a trademark of Sumitomo Pharma Co., Ltd., used under license. SUMITOMO is a registered trademark of Sumitomo Chemical Co., Ltd., used under license. Sumitomo Pharma America, Inc. is a U.S. subsidiary of Sumitomo Pharma Co., Ltd. ©2026 Sumitomo Pharma America, Inc. All rights reserved. References

  1. Daver N, Zeidner JF, Yuda J, et al. Phase 1/2 First-in-Human Study of the Menin-MLL Inhibitor DSP-5336 in Patients with Relapsed or Refractory Acute Leukemia. Blood 2023; 142 (Supplement 1): 2911. Available at: https://doi.org/10.1182/blood-2023179252
  2. Cierpicki T, Grembecka J. Challenges and opportunities in targeting the menin-MLL interaction. Future Med Chem. 2014;6(4):447-462. doi:10.4155/fmc.13.214
  3. Matkar S, Thiel A, Hua X. Menin: a scaffold protein that controls gene expression and cell signaling. Trends Biochem Sci. 2013;38(8):394-402. doi:10.1016/j.tibs.2013.05.005
  4. Eguchi K, Shimizu T, Kato D, et al. Preclinical Evaluation of a Novel Orally Bioavailable Menin-MLL Interaction Inhibitor, DSP-5336, for the Treatment of Acute Leukemia Patients with MLL-Rearrangement or NPM1 Mutation. Blood 2021; 138 (Supplement 1):
  5. Available at: https://doi.org/10.1182/blood-2021-152050
  6. Dutta A, Nath D, Yang Y, et al. Genetic ablation of Pim1 or pharmacologic inhibition with TP-3654 ameliorates myelofibrosis in murine models. Leukemia. 2022;36(3):746-759. doi:10.1038/s41375-021-01464-2
  7. Foulks JM, Carpenter KJ, Luo B, et al. A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas. Neoplasia. 2014;16(5):403-412. doi:10.1016/j.neo.2014.05.004
  8. Scandura JM, Lee J, Hoffman R, et al. Preclinical Evidence of Targeting ACVR1/Hepcidin by Nuvisertib, An Oral Investigational PIM1 Kinase Inhibitor, Suggests Potential Mechanistic Basis for Hemoglobin Benefit in Myelofibrosis. Abstract PF867. Presented at EHA 2026 Congress, 11-15 Jun 2026; Stockholm, Sweden

Prompts

Sumitomo Pharma Co., Ltd. (ticker 4506), listed in Japan.

ETFs Holding Sumitomo Pharma Co., Ltd.

ETF Weight in ETF Shares Market value As of
DFIC 0.01% 162,100 $ 2.001M Nov 12, 2026
DFAI 0.01% 91,500 $ 1.129M Nov 12, 2026
DFAX 0.00% 3,400 $ 41.963K Nov 12, 2026
DFIS 0.00% 29 $ 357.92 Nov 12, 2026
AVDE 0.00% 41,400 $ 519.485K Nov 16, 2026